However, significant risks and considerations must be weighed carefully: Gastrointestinal adverse effects : Both gastric sleeve and semaglutide delay gastric emptying and can cause nausea, vomiting, abdominal discomfort, and constipation
These effects may be mediated by the upregulation of mRNA expression of tight junction proteins in intestinal cells [23] [24]
Injectable semaglutide should be clear, colorless, and free of particles
Although numerous experimental studies, primarily in animal models, have demonstrated the beneficial effects of GLP-1 agonists (e.g., liraglutide and exenatide) in sepsis, including reduced inflammation, improved organ function, and prolonged survival, their clinical use in humans is not yet routine and remains under investigation
While our recent report has shown that over 7% of all prescriptions are for GLP-1-based therapies ( 8 ), oral formulations may lower barriers to initiation by offering a non-injectable option that can be prescribed and managed in a broader range of clinical settings
Tell your healthcare provider that you are taking semaglutide